ducibility, and a reduction in turnaround time from several days to ϳ4 h.
The assay involves RT-PCR with product detection by the 5Ј-nuclease (TaqMan) technology. Thermocycling and signal detection are performed on the ABI Prism 7700 Sequence Detection System, an integrated system consisting of a thermal cycler, a laser for fluorescence induction, and a charge-coupled device detector for the real-time detection of PCR products. Reactions are carried out in the presence of an oligonucleotide probe labeled with two fluorescent dyes, a reporter at the 5Ј end and a quencher at the 3Ј end of the molecule. The structure-specific 5Ј-nuclease activity (16, 17 ) of Taq polymerase digests the probe only when annealed to the specific product generated during PCR amplification. Degradation of the probe separates the reporter dye from the quencher, leading to an increase in fluorescence, which is detected quantitatively in real time by the instrument.
The ability of the instrument to measure fluorescence from several dyes simultaneously allows for multiplex amplifications, with simultaneous detection of different targets in the same reaction. The Sequence Detection System software provided with the instrument analyzes the fluorescence data generated during the reaction and calculates the cycle number at which fluorescence crosses a threshold value determined by analysis of data from early cycles in the amplification process. This cycle number, the threshold cycle (C T ) value, is related to the quantity of specific target in the reaction, with larger quantities of starting material leading to lower C T values.
Assuming the same amplification efficiencies, the relative expression of two genes can be estimated from the difference in C T values, the ⌬C T . The ⌬C T value can be normalized to a control by subtracting the ⌬C T value obtained with the control from that obtained with the test specimen to yield a ⌬⌬C T (18 ) . The assay described in this report involves the determination of a ⌬⌬C T value. C T values for cyclin D1 and ␤ 2 M in the test specimen are compared with those obtained with the MCL cell line M02058, which expresses high amounts of cyclin D1. The greater the ⌬⌬C T value, the lower the expression of cyclin D1 in the specimen. By choosing an appropriate cutoff value for ⌬⌬C T , the assay achieved a sensitivity and a specificity approaching 100% for MCL.
Materials and Methods case selection
Fifty-one cases were selected for study, including 39 formalin-fixed, paraffin-embedded (FFPE) tissues from 1980 to 1997 and 12 fresh tissue samples. Fourteen of the FFPE tissue cases and 6 of the fresh tissue cases were classified as MCL according to the REAL classification (19 ) . Additional data on the individual mantle cell lymphoma cases, including fixation and cyclin D1 expression as determined by immunochemical stain or Northern blot are available as a supplemental table in the online version of this journal (http://www.clinchem.org/content/ vol47/issue2). Twenty-one cases consisted of non-mantlecell lymphomas or leukemias (4 follicular lymphomas, 5 B-cell lymphomas, 5 anaplastic large cell lymphomas, 5 T-cell lymphomas, 1 acute promyelocytic leukemia, and 1 acute lymphocytic leukemia). The remaining 10 cases included 2 atypical lymphoid infiltrates and 8 cases of reactive lymphoid hyperplasia, of which 2 were considered to represent florid reactive hyperplasia. HeLa and Raji cell lines were obtained from the American Type Culture Collection. The M02058 MCL cell line was provided by T.C. Meeker (University of Kentucky, Lexington, KY).
primer and probe design Primer and probe sequences for cyclin D1 and ␤ 2 M are presented in Table 1 . Primers and probes were designed using Primer Express software (PE Applied Biosystems). The cyclin D1 probe was labeled with the reporter dye 6-carboxy fluorescein and the ␤ 2 M probe with the reporter dye VIC. Probes were purchased from PE Applied Biosystems or Integrated DNA Technologies, Inc. For both genes, the primers were placed in different exons to minimize amplification from residual DNA in the RNA preparations. Both the cyclin D1 and ␤ 2 M probes were designed to cross a splice junction to minimize signal generation resulting from amplification of genomic DNA.
rna extraction
To extract RNA from FFPE specimens, six 6-m sections were placed in a 1.5-mL microcentrifuge tube, and the samples were deparaffinized by the addition of 800 L of Hemo-DE (Fisher Scientific) and 400 L absolute ethanol. The tissue fragments were pelleted by centrifugation, the supernatant was decanted, and the pellet washed with 1 mL of absolute ethanol. The supernatant was discarded after centrifugation, and the samples were air-dried. The tissue pellets were digested overnight at 55°C in an extraction buffer containing 20 mmol/L Tris-HCl (pH 7.6), 20 mmol/L EDTA, 10 g/L sodium dodecyl sulfate, and 0.5 g/L Proteinase K (20 ) . Fresh tissue specimens (ϳ20 L tissue volume) were digested in the same extraction buffer. RNA was purified from the digested fresh or paraffin-embedded tissue by TRIzol LS (Gibco/Life Technologies, Ltd.) according to the manufacturer's instructions. RNA was purified from cell lines using the TRIzol reagent. After isopropanol precipitation, the RNA pellet was hydrated in 30 -50 L of diethylpyrocarbonatetreated H 2 O (Research Genetics), incubated at 55°C for 10 min, and stored at Ϫ70°C. RNA used in Northern blot analysis was isolated from fresh tissue according to the procedure described by Chomczynski and Sacchi (21 ) . Lyophilized RNA was resuspended in diethylpyrocarbonate-treated H 2 O to a concentration of 50 ng/L.
M02058 and Raji cells were grown at 37°C in a 5% CO 2 atmosphere in RPMI-1640 medium (Gibco/Life Technologies) supplemented with 100 mL/L fetal calf serum, 2 mmol/L l-glutamine, 0.1 mmol/L sodium pyruvate, 1ϫ MEM nonessential amino acids, 1ϫ MEM vitamins, 100 kilounits/L penicillin, and 100 mg/L streptomycin. Cells were pelleted and washed with 1ϫ Dulbecco's phosphatebuffered saline, counted, and adjusted to 1 ϫ 10 6 cells/ mL. For the experiment shown in Fig. 2 , serial dilutions of M02058 cells were prepared in Raji before RNA isolation. The cells were pelleted in sterile 1.5-mL microcentrifuge tubes, and RNA was extracted using TRIzol as described above.
rt-pcr
Assays were performed in MicroAmp optical reaction tubes and caps (PE Applied Biosystems). Two quantities of each RNA preparation were tested, 1 and 50 ng for the control M02058, or 1 and 3 L of each specimen. Reactions were set up in triplicate at each quantity of RNA, producing six separate RT-PCR reactions for each specimen. RNA was reverse-transcribed with random primers in a 10-L reaction mixture containing the RNA specimen plus 1ϫ PCR Buffer II (PE Applied Biosystems), 5.5 mM MgCl 2 , 100 mM dithiothreitol, 0.125 g of Random Primers (Gibco/Life Technologies), 30 U of M-MLV Reverse Transcriptase, 2 units of RNase inhibitor (Gibco/Life Technologies), and 0.5 mmol/L each dNTP. Reactions were incubated for 60 min at 37°C, heated for 5 min to 95°C, and placed at 4°C.
PCR was performed in a 50-L reaction containing the 10 L of the reverse transcription reaction, 1ϫ Universal PCR Master Mix (PE Applied Biosystems), 15 pmol of each primer, and 5 pmol of each probe. The samples were placed in the ABI Prism 7700 Sequence Analyzer, which was set to detect both 6-carboxy-fluorescein and VIC reporter dyes simultaneously. To increase resolution between the two dyes, the spectral compensation feature was used. After initial incubations at 50°C for 2 min to allow uracil-N-glycosylase digestion and 95°C for 10 min to activate the AmpliTaq Gold, both of which are provided by the Universal PCR Master Mix, the samples were amplified for 40 cycles of 95°C for 15 s, followed by 60°C for 1 min.
data analysis
C T values for each reaction were determined using TaqMan SDS analysis software. For each amount of RNA tested, the triplicate C T values were averaged. Because C T values vary linearly with the logarithm of the amount of RNA, this average represents a geometric mean. The average C T value for ␤ 2 M was subtracted from the average cyclin D1 C T value to yield the ⌬C T value. The ⌬C T values were then averaged for both amounts of sample. The average ⌬C T value for the positive control was then subtracted from the average ⌬C T value of each sample to give the ⌬⌬C T . Three different preparations of the positive control RNA yielded ⌬C T values with a range of 0.46 cycles (SD ϭ 0.23 cycles).
northern blot analysis Total RNA (5 g) from eight fresh tissue samples and two cell lines was electrophoresed through a 1% denaturing formaldehyde agarose gel and transferred to a Hybond-N nylon membrane (Amersham Pharmacia Biotech). The RNA was fixed by ultraviolet cross-linking. The membrane was prehybridized for 2-4 h and hybridized overnight, as described previously (22 ) . The blot was probed with a 1.4-kb BCL-1-specific radiolabeled cDNA probe, PL-8 (23 ) (obtained from A. Arnold, Massachusetts General Hospital, Boston, MA) in the same prehybridization solution with the addition of 100 g/L dextran sulfate. The membranes were rinsed at room temperature in 2ϫ standard saline citrate (1ϫ ϭ 0.15 mol/L NaCl and 0.015 mol/L sodium citrate), washed for 1 h at 65°C in 0.1ϫ standard saline citrate containing 1 g/L sodium dodecyl sulfate, and rinsed in 0.1ϫ standard saline citrate at room temperature, followed by exposure to x-ray film at Ϫ70°C for 1-5 days.
Results
A quantitative real-time RT-PCR assay was designed for the ABI Model 7700 Sequence detection system using the 5Ј-nuclease (TaqMan) technology for signal detection. Primers and probes were designed to avoid amplification and signal generation from genomic DNA. When tested with either 90 ng of HeLa cell or 50 ng of human tonsil genomic DNA, no signal was detected for either ␤ 2 M or cyclin D1, indicating that neither the ␤ 2 M nor the cyclin D1 genes or possible pseudogenes that might be present interfered with this assay. The ⌬C T value obtained from M02058 RNA varied by less than 0.1 cycle in assays Clinical Chemistry 47, No. 2, 2001 containing total cellular RNA quantities ranging from 1 to 50 ng. This result indicates nearly equal amplification efficiencies and validates the ⌬⌬C T approach for quantifying relative amounts of expression (18 ) . Fig. 1 illustrates typical assay results. Triplicate amplifications at one level of lysate for the M02058 control and an FFPE MCL produced nearly identical, overlapping amplification curves, from which C T values were calculated. In this example, the M02058 assay yielded average C T values of 21.6 and 21.8 for cyclin D1 and ␤ 2 M, respectively, for a ⌬C T of Ϫ0.2. The MCL yielded average C T values of 32.2 and 28.6, for a ⌬C T of 3.6. Therefore, for this specimen, the ⌬⌬C T was 3.6 Ϫ (Ϫ0.2) ϭ 3.8.
To evaluate the analytical sensitivity, accuracy, and precision of the assay, ⌬⌬C T values were determined on the serial dilutions of M02058 into Raji. RNA was purified from 10 6 cells from each dilution. Aliquots representing 2 and 6 ϫ 10 4 cells were assayed for cyclin D1 expression in the quantitative RT-PCR assay (Fig. 2) . A cyclin D1 signal first became detectable at ϳ1 in 50 000 cells (0.002%). The within-run CV for the ⌬⌬C T values was Ͻ3% at high, intermediate, and low cyclin D1 expression as estimated from sixfold replicate assays on each of these samples. The SDs of ⌬⌬C T values between runs, estimated by running three dilutions of M02058 into Raji on 5 separate days, were 0.34, 0.34, and 0.56 ⌬⌬C T units for samples having ⌬⌬C T values of 0.91, 3.68, and 12.95, respectively.
The assay was next characterized for its ability to distinguish MCL from other lymphomas and from reactive conditions. Fifty-one cases, including 20 MCLs, were tested for cyclin D1 expression (Table 2 ; results for individual cases available in the supplemental table at http:// www.clinchem.org/content/vol47/issue2). The distribution of ⌬⌬C T values obtained (Fig. 3) indicated that the assay has clinical utility when interpreted relative to a cutoff value chosen to distinguish specimens that show cyclin D1 overexpression from those that do not. of the titration experiment (Fig. 2) indicated that the threshold value of 4.0 would be crossed with a minimum representation of 1.0 -2.5% cyclin D1-overexpressing cells (with cyclin D1 expression equal to or greater than that of M02058) in a background of nonexpressors.
To further evaluate the accuracy of the assay, results obtained by quantitative real-time PCR were compared with Northern blot and semiquantitative RT-PCR results obtained on a subset of the specimens (Table 2) . Consistent with previous results, cyclin D1 expression was observed in all tumors and cell lines tested with the exception of the Raji cell line, in which no cyclin D1 signal was obtained even after 40 cycles of amplification (13, 25 ) . High-quality RNA suitable for Northern blot analysis was available for eight cases. The qualitative amounts cyclin D1 expressed, as determined by Northern blot, were concordant in each case with the results obtained with the quantitative RT-PCR assay. Thirteen of the MCLs, 9 of the non-mantle-cell lymphomas and reactive lymph nodes, and 2 cell lines were assayed by the semiquantitative expression assay reported previously (13 ) . With the single exception of HeLa, which yielded a ⌬⌬C T value Ͻ4.0 but was considered to express an intermediate amount of cyclin D1 by the other methods, there was complete concordance of results among the three assays.
Discussion
The quantitative real-time RT-PCR assay described in this report represents a major improvement over other assays designed to quantify cyclin D1 expression in tissue specimens. The assay is rapid, technically less demanding than previously available methods, and demonstrates a sensitivity and a specificity approaching 100% on lymphoid tissue. The assay therefore has clinical utility in distinguishing MCL from other lymphomas and reactive lymphoid proliferations. An additional advantage provided by this assay is its applicability to FFPE tissue. Neither genomic Southern blotting nor Northern blotting of tumor RNA can be performed successfully with the degraded nucleic acids obtained from fixed and embedded tissue specimens.
Many of the chromosome 11q13 breakpoints in MCL map within a 1-kb region designated the major translocation cluster. The clustering of breakpoints at both 11q13 and 14q32 make detection of the translocation amenable to PCR-based assays (4, 26 ) . However, the 11q13 breakpoints lie within the major translocation cluster in only 30 -50% of cases. Consequently, most PCR-based assays designed to amplify the translocation breakpoint will yield false-negative results for Ͼ50% of MCLs because of breakpoints lying outside of the major translocation clus- (13 ) . The qualitative nature of these methods often does not permit distinction between low and high cyclin D1 expression. Cyclin D1 protein expression has been demonstrated by immunohistochemistry or Western blot in a variety of lymphoproliferative disorders other than MCL, including hairy cell leukemia, plasmacytoma, multiple myeloma, B-cell chronic lymphocytic leukemia, B-prolymphocytic leukemia, plasma cell leukemia, and splenic marginal zone lymphoma (4, (27) (28) (29) (30) (31) (32) . Thus, nonquantitative assays for cyclin D1 protein generally lack specificity for MCL. The results presented in this report demonstrate that this lack of specificity can be overcome by quantitative real-time PCR technology.
In the application of this and other quantitative cyclin D1 assays, it is important to separate lymphoid from epithelial components of the specimen that would typically express cyclin D1 (24 ) . This potential problem is illustrated by the transbronchial biopsy specimen included in this study, which yielded a ⌬⌬C T near the cutoff value of 4.0 because of epithelial cell expression of cyclin D1. A similar phenomenon was observed with an adenoid submitted to our laboratory, in which a ⌬⌬C T Ͻ4.0 was obtained because of expression in the squamous epithelium overlying the lymphoid tissue. It is also important to recognize that, in addition to MCL, cyclin D1 overexpression can occur in other tumors. Overexpression occurs with high frequency in parathyroid adenomas because of an inv11(q13;p13) translocation, which juxtaposes the cyclin D1 gene with the parathyroid hormone gene on 11p13 (23 ) . Overexpression of cyclin D1 has also been demonstrated in some subsets of a variety of solid tumors, including carcinomas of the breast, lung, head and neck, esophagus, and colon (24, 27, 29, 31, (33) (34) (35) (36) (37) .
In conclusion, we have described a quantitative real-time RT-PCR assay for cyclin D1 expression. The assay was shown to have a sensitivity and a specificity of nearly 100% on lymphoid tissue specimens. The assay is rapid and easy to perform relative to alternative technologies and has clinical utility in distinguishing MCL from other lymphomas and reactive lymphoid proliferations.
